Skip to main content
SpringerLink
Log in

Rivaroxaban use following bariatric surgery

  • Letter to the Editor
  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mahlmann A, Gehrisch S, Beyer-Westendorf J (2013) Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. J Thromb Thrombolysis 36:533–535

    Article  PubMed  Google Scholar 

  2. Stampfuss J, Kubitza D, Becka M, Mueck W (2013) The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 51:549–561

    Article  CAS  PubMed  Google Scholar 

  3. Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46:549–558

    Article  CAS  PubMed  Google Scholar 

  4. Xarelto Prescribing Information (2013). http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf. Accessed 17 Dec 2013

  5. Protocol for: Patel MR, Mahaffey KW, Garg J, et al. (2013) Rivaroxaban versus warfarin in nonvalvular atrial abrillation. N Engl J Med 2011; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1009638/suppl_file/nejmoa1009638_protocol.pdf. Accessed 17 Dec 2013

  6. Protocol for: The EINSTEIN–PE investigators (2013). Oral rivaroxaban for the treatment of symptomatic pulmonary. N Engl J Med 2012; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1113572/suppl_file/nejmoa1113572_protocol.pdf. Accessed 17 Dec 2013

  7. Protocol for: The EINSTEIN investigators (2013). Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1007903/suppl_file/nejmoa1007903_protocol.pdf. Accessed 17 Dec 2013

  8. Centers for Disease Control and Prevention (2013). National Health and Nutrition Examination Survey. Intake of calories and selected nutrients for the United States Population, 1999–2000. http://www.cdc.gov/nchs/data/nhanes/databriefs/calories.pdf. Accessed 17 Dec 2013

  9. Finks JF, English WJ, Carlin AM, Krause KR, Share DA, Banerjee M, Birkmeyer JD, Birkmeyer NJ (2012) Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. Ann Surg 255:1100–1104

    Article  PubMed  Google Scholar 

  10. Magnani JW, Hylek EM, Apovian CM (2013) Obesity begets atrial fibrillation: a contemporary summary. Circulation 128:401–405

    Article  PubMed  Google Scholar 

  11. Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol 47:218–226

    Article  CAS  PubMed  Google Scholar 

  12. University of California San Francisco (2013). Dietary guidelines after bariatric surgery. http://www.ucsfhealth.org/education/dietary_guidelines_after_gastric_bypass/. Accessed 17 Dec 2013

  13. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA (1997) Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 157:2562–2568

    Article  CAS  PubMed  Google Scholar 

  14. Smith SB, Geske JB, Maguire JM, Zane NA, Carter RE, Morgenthaler TI (2010) Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 137:1382–1390

    Article  PubMed Central  PubMed  Google Scholar 

  15. Hylek EM, Skates SJ, Sheehan MA, Singer DE (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540–546

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Drs. Bareket and Thomas report receiving consulting fees from Janssen Pharmaceuticals, the manufacturer of rivaroxaban.

Author information

Authors and Affiliations

  1. Hackensack University Medical Center, 30 Prospect Avenue, Hackensack, NJ, 07601, USA

    Zachariah Thomas, Yaron Bareket & Wendy Bennett

  2. Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA

    Zachariah Thomas

Authors
  1. Zachariah Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yaron Bareket
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wendy Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zachariah Thomas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomas, Z., Bareket, Y. & Bennett, W. Rivaroxaban use following bariatric surgery. J Thromb Thrombolysis 38, 90–91 (2014). https://doi.org/10.1007/s11239-014-1057-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-014-1057-6

Keywords

Search

Navigation